Parkinson Disease

More studies are needed to show conclusive benefits on patient functionality.

Pimavanserin is an atypical antipsychotic indicated for the treatment of Parkinson disease-associated hallucinations and delusions.

The CBD gummy market is being fueled by the desire for alternative, natural treatment options.

Psilocybin is derived from certain types of mushrooms and has been proven to affect serotonin receptors.

Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Although the treatment of motor symptoms is the primary focus of care for Parkinson disease, helping these patients with sleep disorders is vital because of the impact on quality of life.

Antioxidants are capable of converting highly destructive free radicals and nonradical molecules, thereby reducing cerebral stress.

Research suggests that acupuncture may be able to clinically reduce symptoms of anxiety in this patient population.

With the help of pharmacists and a team of health care providers, a better quality of life is possible for patients with Parkinson disease.

They can assess for adherence, identify drug-related problems, monitor pharmacotherapy, and provide education.

Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.

Dhivy is a levodopa/carbidopa combination formulation approved by the FDA in November 2021 for the treatment of Parkinson disease or manifestations due to viral or environmental exposures.

The guidance updates the recommendations on dopaminergic medications that were published in 2002 on the initiation treatment for Parkinson disease.

The results of the study are consistent with several large-scale epidemiological studies that show an association between Parkinson and inflammatory bowel diseases, such as ulcerative colitis and Crohn disease.

April is Parkinson’s Awareness Month, so what better time to refresh your understanding and promote awareness around Parkinson disease than now?

The study compared step impairments across the cognitive spectrum, including people with subjective cognitive impairment, Parkinson disease, mild cognitive impairment, Alzheimer disease, Lewy body dementia, and frontotemporal dementia, as well as cognitively healthy controls.

Studies have shown that patients with Parkinson disease admitted to the hospital experience longer hospital stays and increased mortality than age matched control groups.

The increased risk may be due to changes in the brain’s dopamine system caused by dopamine receptor antagonists or neurobiological effects of schizophrenia.

Research has also shown that patients with Parkinson disease who are able to engage in physical activity can potentially improve the motor and non-motor symptoms associated with the disease.

Seven cases of young people with stiffness throughout their body and an inability to speak presented to hospitals in different cities throughout the country, with seemingly no link between them.

New treatment options offer hopes of better clinical outcomes for patients suffering from Parkinson disease and its debilitating daily symptoms.

Officials with the FDA have approved apomorphine hydrochloride sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease.

Individuals with the progressive condition often struggle to control their motor fluctuations.

Pharmacists play an integral role and can improve patients’ quality of life with proper communication, counseling, and monitoring.

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.